Vaporox, Inc.
$51.8K 102 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Merakris Therapeutics, Inc.
Merakris Therapeutics, Inc. reported $51,784.50 across General Payments, Research, and Ownership to 9 physicians and teaching hospitals across 11 transactions.
- $51.8K Below-median payer
- All-tracks total
- 11 Below-median volume
- Transactions
- 9 Below-median reach
- Recipients
- +$10.0K
- General Payments vs PY2023
Merakris Therapeutics, Inc. reported $51,784.50 across all CMS Open Payments tracks (General + Research + Ownership) to 9 physicians and teaching hospitals in Program Year 2024 - ranking #1341 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $10,362.50, averaging $5.8K per recipient.
How Merakris Therapeutics, Inc.'s $51.8K all-tracks total breaks down
Merakris Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer merakris-therapeutics-inc Merakris Therapeutics, Inc.
$51.8K · #1341/1,925 · 0.0% industry · PY2024
- TOT $51.8K
- RANK #1341
- SHARE 0.0%
- TXN 11
- RCP 9
- CAT 2
- GEN $10.4K
- ΔGEN +$10.0K
- TOP1 51.1%
- PY 2024
Volume peers
Nearest volume peer: Vaporox, Inc. ($51.8K)
Merakris Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Merakris Therapeutics, Inc.'s CMS-reported General Payments increased by $10.0K (+2516.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: MERAKRIS THERAPEUTICS, INC.PY2024: Merakris Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $396.00
- PY2024
- $10,362.50
What the Data Shows for Merakris Therapeutics, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Merakris Therapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $5.3K, accounting for 51.1% of this company's General Payments and 4 transactions.
General Payment Breakdown by Type
Merakris Therapeutics, Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $5.3K, 51.1% of General Payments.
How Merakris Therapeutics, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $5.3K | 4 | 51.1% |
| Compensation for Services Other Than Consulting | $5.1K | 5 | 48.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $10,237.50 (98.8%) of $10,362.50 in this company's General Payments records across 6 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Merakris Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Sharon Yvonne Hook
$5,300.00 across 4 reported transactions
- 2
Sarah Ducharme
$3,000.00 across 1 reported transactions
- 3
Jengyu Lai
$1,500.00 across 1 reported transactions
- 4
Linda Rose
$250.00 across 1 reported transactions
- 5
Jeffrey Richard Varanelli
$187.50 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Merakris Therapeutics, Inc. ranks #1341 of 1,925 by total payments (bottom 30% by spend) but is notably more concentrated than that alone would suggest -- #481 of 1,838 by HHI (top 26% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Elekta Pty Ltd : $117.64 total payments, HHI 3726
- Aegis Spine, Inc. : $334.3K total payments, HHI 3714
- One Lambda, Inc. : $150.1K total payments, HHI 3711
- Nurami Medical Ltd : $627.48 total payments, HHI 3707
- Pristine Surgical LLC : $19.0K total payments, HHI 3684
- Circle Cardiovascular Imaging Inc. : $14.6K total payments, HHI 3678
- Merakris Therapeutics, Inc. (this company) : $10.4K total payments, HHI 3674
- aap Implants Inc : $631.69 total payments, HHI 3671
- Polarean, Inc. : $131.4K total payments, HHI 3654
- AccuTec Blades Inc : $45.1K total payments, HHI 3645
- Epizyme, Inc. : $16.4K total payments, HHI 3641
- OrphAI Therapeutics Inc. : $24.4K total payments, HHI 3624
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Merakris Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Merakris Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Merakris Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
United Imaging Healthcare North America LLC
$51.7K 170 recipients
Compare payment profiles
Infinity BiologiX LLC
$52.4K 9 recipients
Compare payment profiles
Steelhead Surgical Inc
$51.2K 378 recipients
Compare payment profiles
Roche Diabetes Care GmbH
$52.4K 31 recipients
Compare payment profiles
Seagen Inc.
$52.4K 561 recipients
Compare payment profiles
Put this to use
Merakris Therapeutics, Inc. ranks #1341 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Merakris Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.